ロード中...
Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study
We formulated a traditional Chinese medicine (TCM) prescription, Hanshiyi Formula (HSYF), which was approved and promoted by the Wuhan Municipal Health Commission for treating mild and moderate coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of HSYF on the progression to severe...
保存先:
| 出版年: | Pharmacol Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier Ltd.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416080/ https://ncbi.nlm.nih.gov/pubmed/32791263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2020.105127 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|